

CLAIMS (as amended)

20. A method for arresting or reducing the advancement, severity or effects of a tumor comprising the administration to a subject of an effective amount of a composition which inhibits the interaction between LT- $\beta$  and its receptor.
21. The method of claim 20 wherein said tumor is follicular lymphoma.
22. The method of claim 21 wherein the composition is selected from the group consisting of a soluble LT-  $\beta$  receptor, anti-LT - $\alpha$  antibodies, anti -LT-  $\beta$  -antibodies, and anti-LT-  $\beta$  -R antibodies.
23. The method of claim 22 wherein the composition is a soluble LT- $\beta$  receptor.
24. The method of claim 20 wherein the subject is a mammal.
25. The method of claim 24 wherein the subject is a human.
26. The method according to claim 23 wherein the soluble lymphotoxin-  $\beta$  receptor comprises a ligand binding domain that can selectively bind to a surface LT ligand.
27. The method according to claim 26 wherein the LT-  $\beta$  -receptor comprises a human immunoglobulin FC domain.
28. The method according to claim 22 wherein the composition comprises a monoclonal antibody directed against an LT-  $\beta$  receptor.
29. The method of claim 28 wherein the monoclonal antibody is humanized or chimeric.
30. A composition for the treatment of a subject having follicular lymphoma which blocks the interaction of LT-  $\beta$  with its receptor.
31. The method of claim 20 comprising the administration to said subject of at least one chemotherapeutic agent.
32. The method of claim 20 comprising the administration to said subject of radiation treatments.
33. The method of claim 20 further comprising the administration to said subject of radiation treatments or bone marrow transplantation.
34. A method for altering the survival or maintenance of follicular dendritic cells in a subject comprising administering an inhibitor of the interaction between LT-  $\beta$  and its receptor.
35. A method for altering the architecture of the organs of the immune system by administering (a) an inhibitor of the interaction between LT-  $\beta$  and its receptor; and (b) an inhibitor of the signaling pathway of an additional member of the TNF family of ligands and receptors.